Table 1.
Patient characteristics.
| Variable | N = 1961 | % |
|---|---|---|
| Gender | ||
| Female | 826 | 42% |
| Male | 1135 | 58% |
| Age at molecular diagnosis | ||
| Median (min–max) | 69 (23–90) | |
| Stage | ||
| Early (IA–IIIA) | 513 | 26% |
| Advanced (IIIB–IV) | 1448 | 74% |
| Type of panel | ||
| 22 Genes | 1745 | 89% |
| Focus | 202 | 10% |
| Both | 14 | 1% |
| EGFR | 270/1961 | 13.8% |
| ALK | 107/1951 | 5.5% |
| ROS1 | 9/1956 | 0.5% |
| BRAF | 71/1890 | 3.8% |
| V600E | 24/1890 | 1.3% |
| Other variant | 47/1890 | 2.7% |
| KRAS | 536/1961 | 27.3% |
| G12C | 199/1961 | 10.1% |
| Other variant | 337/1961 | 17.2% |
| MET exon 14 skipping | 13/207 | 6.3% |
| RET fusions | 7/207 | 3.4% |
| TP53 | 454/1759 | 25.8% |
| PIK3CA | 75/1961 | 3.8% |
| ERBB2 | 17/1961 | 0.9% |
| PD-L1 | ||
| score 0 (<1%) | 568/1351 | 42.0% |
| score 1 (1–49%) | 512/1351 | 37.8% |
| score 2 (≥50%) | 271/1351 | 20.2% |